Research programme: dioxygenase inhibitors - NewLink Genetics

Drug Profile

Research programme: dioxygenase inhibitors - NewLink Genetics

Alternative Names: Ethyl pyruvate - NewLink Genetics; Indoleamine-2,3-dioxygenase (IDO) pathway inhibitors - NewLink Genetics; NLG-802; Tryptophan-2,3-dioxygenase inhibitors - NewLink Genetics

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer Genentech; Lankenau Institute for Medical Research; NewLink Genetics Corporation
  • Class Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Hepatitis C; HIV infections

Most Recent Events

  • 25 May 2017 NewLink Genetics Corporation plans a phase I trial for Solid tumours(Late-stage disease) in USA (NCT03164603)
  • 04 May 2017 NewLink Genetics plans clinical trials of NLG 802 by the end of third quarter of 2017
  • 04 Apr 2017 Pharmacokinetics data from a preclinical trial in cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top